Source:http://linkedlifedata.com/resource/pubmed/id/17508034
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-5-17
|
pubmed:abstractText |
A recent phase I trial of an encapsulated cell therapy device that delivers ciliary neurotrophic factor has shown the potential of this approach in the treatment of retinitis pigmentosa. As experience with this device is gained, other retinal degenerative disorders may be potential targets of a similar therapeutic approach.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-4182
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
399-402
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading | |
pubmed:year |
2007
|
pubmed:articleTitle |
Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants.
|
pubmed:affiliation |
National Eye Institute, National Institute of Health, Bethesda, MD 20892-1860, USA. macdonaldi@mail.nih.gov
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, N.I.H., Extramural,
Research Support, N.I.H., Intramural
|